Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CFTR | P13569 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441687 | 1.00 | SLC6A3 (0.61) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL30285287 | 0.89 | SLC6A3 (0.71) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL28409137 | 0.88 | GAA (0.50) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL27843639 | 0.85 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL6434822 | 0.84 | MAPT (0.54) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL15266628 | 0.83 | SLC6A3 (0.63) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL30285097 | 0.83 | SLC6A3 (0.63) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL3784759 | 0.82 | ALOX5AP (0.49) | ALDH1A1MAPTMEN1KMT2AGRM5 | |
| SCHEMBL1854430 | 0.82 | SLC6A3 (0.71) | SLC6A3SLC6A4SLC6A2ALDH1A1CFTR | |
| SCHEMBL6434824 | 0.81 | MAPT (0.49) | SLC6A3SLC6A4SLC6A2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3607950-A2 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research & Technology Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3607950-A2 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research & Technology Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3116316-B1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | UNIV INDIANA RES & TECH CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3116316-B1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | UNIV INDIANA RES & TECH CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-01-05 | — | — | US | disclosed |
| EP-1087943-B1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | EP | disclosed |
| EP-1443934-B1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-04-20 | — | — | EP | disclosed |
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101533-A1 | 1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1443934-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
| US-6251925-B1 | AN AGONISTS FOR HUMAN BETA-3 ADRENOCEPTOR | GLAXO WELLCOME INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1087943-A1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065877-A1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC13A3, CLIC1 | SLC6A3 255/4885SLC6A4 185/4885SLC6A2 197/4885 |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | SLC6A3 4663/4885SLC6A4 4315/4885SLC6A2 4602/4885 |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | SLC6A3 4663/4885SLC6A4 4315/4885SLC6A2 4602/4885 |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | SLC6A3 950/4885SLC6A4 630/4885SLC6A2 1004/4885 |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | SLC6A3 4663/4885SLC6A4 4315/4885SLC6A2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.